Manipal Health's 13% rally on IPO debut makes investors richer by ₹10,000 crore
ADVERTISEMENT
Manipal Health Enterprises delivered a strong market debut on Wednesday, with its shares ending 13% above the issue price and adding ₹10,063 crore to investors' wealth in a single trading session.
The multispecialty hospital operator closed at ₹666.70 on the BSE, up 13% over its IPO price of ₹590. The stock had debuted at ₹655, a premium of 11.02%, and rallied as much as 14.58% during the day to touch an intraday high of ₹676.05 before settling lower. It hit an intraday low of ₹634.55.
The company's market capitalisation rose to ₹87,696.20 crore at the close, compared with ₹77,633.56 crore at the IPO price. More than 43.91 lakh shares changed hands on the BSE during the session.
The listing comfortably exceeded grey market expectations. Ahead of its debut, the stock was commanding a grey market premium (GMP) of around ₹3, implying an expected listing price of about ₹593 per share, or a modest premium of 0.51%.
The broader market also ended in the green after the Reserve Bank of India (RBI) kept the benchmark repo rate unchanged at 5.25% and retained its neutral policy stance, in line with market expectations. The Nifty50 gained 9.75 points, or 0.04%, to close at 24,624.65, while the BSE Sensex rose 152.05 points, or 0.19%, to settle at 78,581.00.
IPO subscribed 4.92x on institutional backing
Manipal Health's ₹9,275-crore IPO, open between July 29 and July 31, was subscribed 4.92 times, driven largely by institutional investors. The qualified institutional buyers (QIB) portion was subscribed 8.25 times, while the non-institutional investor (NII) category was subscribed 1.02 times. Retail participation remained subdued, with the retail individual investor (RII) segment subscribed 0.93 times.
The public issue comprised a fresh issue of ₹8,000 crore and an offer for sale (OFS) of up to 2.16 crore shares by existing shareholders, including promoters Imperius Healthcare Investments and Manipal Education and Medical Group India, along with investors such as TPG SG Magazine, Novo Holdings Invest Asia, Seventy Second Investment Company LLC, Ammar Sdn Bhd and Phoenix Bear Investments.
Analysts see long-term potential, advise caution on valuations
Analysts said the stronger-than-expected listing reflects investor confidence in India's structural healthcare growth story, though they cautioned that the stock's premium valuation leaves limited room for error.
Ravi Singh, Chief Research Officer at Master Capital Services, said the healthy listing premium highlights the market's optimism around Manipal Health's leadership in India's hospital sector. He cited the company's pan-India network of 49 hospitals with more than 13,000 licensed beds, improving operational efficiencies and plans to add 2,426 beds by 2030 as key growth drivers.
"The company is well positioned to benefit from the long-term expansion of India's healthcare delivery market. However, investors should closely monitor quarterly earnings and margin sustainability amid competitive pricing pressures. The stock is better suited for long-term, growth-oriented portfolios," Singh said.
Shivani Nyati, Head of Wealth at Swastika Investmart, said that despite the encouraging debut, the stock is trading at a premium valuation with a limited margin of safety.
She noted that a large part of the IPO proceeds will be used to repay acquisition-related debt, leaving relatively less capital for future expansion. She also highlighted the company's significant dependence on Karnataka for revenue.
"Investors who received allotment can continue to hold the stock, while fresh investors should wait for better entry levels or further progress on debt reduction before taking exposure. A stop-loss at ₹620 may be maintained to protect listing gains," Nyati said.
(DISCLAIMER: The views and opinions expressed by investment experts on fortuneindia.com are either their own or of their organisations, but not necessarily that of fortuneindia.com and its editorial team. Readers are advised to consult certified experts before taking investment decisions.)